Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer.

IF 1.2 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Danish medical journal Pub Date : 2025-09-18 DOI:10.61409/A11240821

Laurits Sebastian Dahl, Ann Søegaard Knoop, Maj-Britt Jensen, Eva Harder, Jeanette Dupont Rønlev, Tobias Berg

{"title":"Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer.","authors":"Laurits Sebastian Dahl, Ann Søegaard Knoop, Maj-Britt Jensen, Eva Harder, Jeanette Dupont Rønlev, Tobias Berg","doi":"10.61409/A11240821","DOIUrl":null,"url":null,"abstract":"Introduction: Tucatinib in combination with trastuzumab and capecitabine is approved for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer in third-line and later based on the results of the HER2CLIMB trial. In this short report, we evaluate the extent and efficacy of tucatinib treatment among Danish patients.Methods: This is a retrospective study that includes all known Danish patients who initiated tucatinib prior to June 1, 2024. We utilised the nationwide clinical database of the Danish Breast Cancer.Results: In total, 38 patients were treated. Nineteen (50%) of the patients had central nervous system (CNS) metastases, and 21 (55%) had visceral disease. Median progression-free survival was 8.7 months (95% CI: 6.2; 13.3) and median overall survival was 22.4 months (95% CI: 13.1; N/A). Nine patients exhibited a performance status of 2-3 (n = 5) or uncontrollable CNS metastases (n = 4), not meeting the inclusion criteria applied in the HER2CLIMB trial.Conclusions: Our results align with data presented from the HER2CLIMB trial. Considerably fewer patients than initially expected have been treated in Denmark.Funding: None.Trial registration: Approved by the Capital Regions Research Overview (P-2024-175774) and the Centre for Health Research (R-24065900).","PeriodicalId":11119,"journal":{"name":"Danish medical journal","volume":"72 10","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61409/A11240821","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Tucatinib in combination with trastuzumab and capecitabine is approved for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer in third-line and later based on the results of the HER2CLIMB trial. In this short report, we evaluate the extent and efficacy of tucatinib treatment among Danish patients.

Methods: This is a retrospective study that includes all known Danish patients who initiated tucatinib prior to June 1, 2024. We utilised the nationwide clinical database of the Danish Breast Cancer.

Results: In total, 38 patients were treated. Nineteen (50%) of the patients had central nervous system (CNS) metastases, and 21 (55%) had visceral disease. Median progression-free survival was 8.7 months (95% CI: 6.2; 13.3) and median overall survival was 22.4 months (95% CI: 13.1; N/A). Nine patients exhibited a performance status of 2-3 (n = 5) or uncontrollable CNS metastases (n = 4), not meeting the inclusion criteria applied in the HER2CLIMB trial.

Conclusions: Our results align with data presented from the HER2CLIMB trial. Considerably fewer patients than initially expected have been treated in Denmark.

Funding: None.

Trial registration: Approved by the Capital Regions Research Overview (P-2024-175774) and the Centre for Health Research (R-24065900).

查看原文本刊更多论文

图卡替尼治疗丹麦人表皮生长因子受体2阳性转移性乳腺癌的实际疗效。

基于HER2CLIMB试验的结果，图卡替尼联合曲妥珠单抗和卡培他滨被批准用于三线及后期转移性人表皮生长因子受体2 （HER2）阳性乳腺癌的治疗。在这篇简短的报告中，我们评估了图卡替尼治疗丹麦患者的程度和疗效。方法：这是一项回顾性研究，包括所有已知的在2024年6月1日之前开始使用图卡替尼的丹麦患者。我们使用了丹麦乳腺癌的全国临床数据库。结果：共治疗38例。19例（50%）患者有中枢神经系统（CNS）转移，21例（55%）有内脏疾病。中位无进展生存期为8.7个月（95% CI: 6.2; 13.3），中位总生存期为22.4个月（95% CI: 13.1；无）。9例患者表现为2-3 （n = 5）或不可控的中枢神经系统转移（n = 4），不符合HER2CLIMB试验的纳入标准。结论：我们的结果与HER2CLIMB试验的数据一致。在丹麦接受治疗的患者比最初预期的要少得多。资金:没有。试验注册：由首都地区研究概况（P-2024-175774）和卫生研究中心（R-24065900）批准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Danish medical journal MEDICINE, GENERAL & INTERNAL-

CiteScore

2.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： The Danish Medical Journal (DMJ) is a general medical journal. The journal publish original research in English – conducted in or in relation to the Danish health-care system. When writing for the Danish Medical Journal please remember target audience which is the general reader. This means that the research area should be relevant to many readers and the paper should be presented in a way that most readers will understand the content. DMJ will publish the following articles: • Original articles • Protocol articles from large randomized clinical trials • Systematic reviews and meta-analyses • PhD theses from Danish faculties of health sciences • DMSc theses from Danish faculties of health sciences.